Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-specific peptidase 4 (USP4) is a multidomain cysteine protease within the deubiquitinating enzyme (DUB) family, responsible for removing monoubiquitinated and polyubiquitinated chains (such as K48 and K63 linkages) from substrate proteins. USP4 regulates several critical cellular processes, including signal transduction (in the NF-κB, TGF-β, and Wnt/β-catenin pathways), spliceosome activity, DNA repair via homologous recombination, and cell fate determination. It shuttles between the cytoplasm and nucleus and is tightly regulated by post-translational modifications (such as phosphorylation and ubiquitination). Aberrant USP4 expression or mutation is linked to the progression and poor prognosis of various cancers and immune disorders. Efforts are ongoing to develop selective USP4 inhibitors as novel therapeutics for cancer and inflammatory diseases[1][3][4][5][6][7].
Inhibition leads to increased ubiquitination and degradation of signaling proteins (e.g., BRCA1, TGF-β receptor, NF-κB pathway components), modulating cell survival, proliferation, and immune signaling[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-specific peptidase 4 (USP4).